Vertex Pharmaceuticals
VRTX
1,560 hedge funds and large institutions have $107B invested in Vertex Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 120 funds opening new positions, 616 increasing their positions, 610 reducing their positions, and 149 closing their positions.
68% more call options, than puts
Call options by funds: $930M | Put options by funds: $554M
1% more repeat investments, than reductions
Existing positions increased: 616 | Existing positions reduced: 610
0.26% more ownership
Funds ownership: 93.55% → 93.81% (+0.26%)
3% less funds holding
Funds holding: 1,613 → 1,560 (-53)
8% less capital invested
Capital invested by funds: $116B → $107B (-$9.23B)
19% less first-time investments, than exits
New positions opened: 120 | Existing positions closed: 149
38% less funds holding in top 10
Funds holding in top 10: 26 → 16 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$915M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$858M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$724M |
| 4 |
Jennison Associates
New York
|
+$502M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$234M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Amundi
Paris,
France
|
-$906M |
| 2 |
JP Morgan Chase
New York
|
-$869M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$609M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$341M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$296M |
VRTX Hedge Fund Activity: Q2 2025 in Review
1,560 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2025, worth a combined $107B — down 7.9% from $116B a quarter earlier.
Sellers outnumbered buyers: 149 funds closed out of VRTX and 120 opened new positions — a net loss of 29 holders — while 610 trimmed existing stakes and 616 added.
The largest buyer was Capital International Investors, adding an estimated $915M. The largest seller was Amundi, cutting an estimated $906M.
- 1,560 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2025, down from 1,613 in Q1 2025.
- Funds reported $107B of Vertex Pharmaceuticals stock for Q2 2025, down 7.9% quarter-over-quarter.
- 120 funds opened new Vertex Pharmaceuticals positions in Q2 2025 and 149 closed out, a net change of -29 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2025 was Capital International Investors, an estimated $915M added.
- The largest Vertex Pharmaceuticals seller in Q2 2025 was Amundi, an estimated $906M sold.
Based on aggregated 13F filings for Q2 2025.